BAFF / BLyS Protein, Human, Recombinant (Fc Tag)

1/2
Price:
Size:
Number:

BAFF / BLyS Protein, Human, Recombinant (Fc Tag): Product Information

Purity
> 95 % as determined by SDS-PAGE
Endotoxin
< 1.0 EU per μg of the protein as determined by the LAL method
Activity
1. Measured by its binding ability in a functional ELISA. Immobilized recombinant human BAFF at 1 μg/mL (100 μl/well) can bind human TNFRSF17. The EC50 of human TNFRSF17 is 0.07 μg/mL.
2. Measured in a cell proliferation assay in mouse splenocytes. The ED50 for this effect is typically 0.6-3.2 ng/mL.
Protein Construction
A DNA sequence encoding the soluble form of human BAFF (Q9Y275-1) (Ala 134-Leu 285) was fused with the Fc region of human IgG1 at the N-terminus.
Accession#
Expressed Host
HEK293 Cells
Species
Human
Predicted N Terminal
Glu 20
Molecule Mass
The recombinant human BAFF/Fc is a disulfide-linked homodimeric protein. The reduced monomer consists of 389 amino acids and has a predicted molecular mass of 43.7 kDa. In SDS-PAGE under reducing conditions, the apparent molecular mass of rhBAFF/Fc monomer is approximately 48-55 kDa due to glycosylation.
Formulation
Lyophilized from sterile PBS, pH 7.4
Please contact us for any concerns or special requirements.
Normally 5 % - 8 % trehalose, mannitol and 0.01% Tween80 are added as protectants before lyophilization.
Please refer to the specific buffer information in the hard copy of CoA.
Shipping
In general, recombinant proteins are provided as lyophilized powder which are shipped at ambient temperature.
Bulk packages of recombinant proteins are provided as frozen liquid. They are shipped out with blue ice unless customers require otherwise.
Stability & Storage
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃
Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
Reconstitution
A hardcopy of COA with reconstitution instruction is sent along with the products. Please refer to it for detailed information.

BAFF / BLyS Protein, Human, Recombinant (Fc Tag): Images

Measured in a cell proliferation assay in mouse splenocytes. The ED50 for this effect is typically 0.6-3.2 ng/mL.

BAFF / BLyS Protein, Human, Recombinant (Fc Tag): Alternative Names

BAFF Protein, Human; BLYS Protein, Human; CD257 Protein, Human; DTL Protein, Human; TALL-1 Protein, Human; TALL1 Protein, Human; THANK Protein, Human; TNFSF20 Protein, Human; ZTNF4 Protein, Human

BAFF / BLyS Background Information

B lymphocyte stimulator (BLyS), also known as TNFSF13B, CD257 and BAFF, is single-pass type II membrane protein, which belongs to the tumor necrosis factor family. BAFF is abundantly expressed in peripheral blood Leukocytes and is specifically expressed in monocytes and macrophages. BAFF is a cytokine and serves as a ligand for receptors TNFRSF13B (TACI), TNFRSF17 (BCMA), and TNFRSF13C (BAFFR). These receptors is a prominent factor in B cell differentiation, homeostasis, and selection. BLyS levels affect survival signals and selective apoptosis of autoantibody-producing B cells. Thus, it acts as a potent B cell activator and has been shown to play an important role in the proliferation and differentiation of B cells. Overexpression of BLyS in mice can lead to clinical and serological features of systemic lupus erythematosus (SLE) and Sjögren's syndrome (SS). BLyS as an attractive therapeutic target in human rheumatic diseases. The ability of BLyS to regulate both the size and repertoire of the peripheral B cell compartment raises the possibility that BLyS and antagonists thereof may form the basis of a therapeutic trichotomy. As an agonist, BLyS protein may enhance humoral immunity in congenital or acquired immunodeficiencies such as those resulting from viral infection or cancer therapy.
Full Name
tumor necrosis factor (ligand) superfamily, member 13b
Research Areas
References
  • Nardelli B, et al. (2002) B lymphocyte stimulator (BLyS): a therapeutic trichotomy for the treatment of B lymphocyte diseases. Leuk Lymphoma. 43(7): 1367-73.
  • Stohl W. (2006) Therapeutic targeting of B lymphocyte stimulator (BLyS) in the rheumatic diseases. Endocr Metab Immune Disord Drug Targets. 6(4): 51-8.
  • Cancro MP, et al. (2009) The role of B lymphocyte stimulator (BLyS) in systemic lupus erythematosus. J Clin Invest. 119(5): 1066-73.
Add to Cart Successfully Add to Cart Failed Shopping cart is being updated, please wait